In practice, lecanemab, an anti-Aβ antibody, which has been shown to slow cognitive decline in patients with early-stage AD, reduces total tau protein and P-Tau181 levels in cerebrospinal fluid.[10] This suggests that Aβ contributes to the effect of tau in AD. Here, MAPT is linked to Alzheimer disease.